Skip to content

Psilocybin: all studies

Page 64 of 439: studies 631 to 640 of 4,389, newest first. Back to the psilocybin overview

Research

Psilocybin’s acute and persistent brain effects: a precision imaging drug trial

Scientific Data June 5, 2025 Subha Subramanian, Travis Rick Renau, Demetrius Perry et al. 4 citations

Psilocybin (PSIL) is a psychedelic drug and a promising experimental therapeutic for many psychiatric conditions. Precision functional mapping (PFM) combines densely repeated resting state fMRI sampling and individual-specific network mapping to improve signal-to-noise ratio (SNR) and effect size in brain imaging research. We present a randomized cross-over study in which PFM was used to...

Towards "unmakable" psychedelics: SAR exploration of psilocin analogs obtained by a HATU-mediated amide coupling strategy

European Journal of Medicinal Chemistry Reports June 3, 2025 Judith Stirn, Raphael Berger, Harald Hübner et al. 1 citation

4-Hydroxytryptamines such as psilocin and its prodrug psilocybin are of considerable current interest for innovative antidepressant and other neuropsychiatric treatments. We here present a synthetic route towards 4-hydroxytryptamines displaying a high versatility for SAR exploration at the aliphatic nitrogen. The core concept is to apply HATU-mediated amide couplings to a readily accessible and...

Effects of Psilocybin on Mouse Brain Microstructure.

AJNR. American journal of neuroradiology June 3, 2025 Paloma C Frautschi, Ajay P Singh, Nicholas A Stowe et al. 2 citations

There is surging interest in the therapeutic potential of psychedelic compounds like psilocybin in the treatment of psychiatric illnesses like major depressive disorder (MDD). Recent studies point to the rapid antidepressant effect of psilocybin; however, the biologic mechanisms underlying these differences remain unknown. This study determines the feasibility of using diffusion MRI to...

Exploring the Therapeutic Potential of Psilocybin and Ketamine in Major Depressive Disorder including Treatment-Resistant Depression: A Narrative Review

Biuletyn Głównej Biblioteki Lekarskiej June 1, 2025 Christian S. Skowron, Urszula Miłkowska, Gabriela Maria Piech et al.

Abstract Major depressive disorder (MDD), including treatment-resistant depression (TRD), represents significant global health challenges with conventional therapies often yielding suboptimal outcomes. This narrative review examines the therapeutic potential of psilocybin and ketamine, two novel agents offering distinct mechanisms of action compared to traditional monoamine-based or monoamine...

Characterization and Identification of an Antimicrobial Compound Psilocybin from Psychedelic Mushroom.

Indian journal of microbiology June 1, 2025 Balakrishnan Karthiyayini, Nalliah Nithya Kalyani, Balakrishnan Gowdhami et al. 2 citations

The antimicrobial compound psilocybin possesses psychoactive properties with therapeutic applications. Psilocybin is the main component naturally present in psychedelic mushrooms and has been utilized in the treatment of depression and neurological disorders. In this study, psychedelic mushrooms were collected from Kodaikanal, Tamil Nadu. They underwent solvent extraction using High Performance...

DOI: 10.1007/s12088-024-01396-2 (opens in new tab) Full text (opens in new tab) Psychedelic mushrooms Minimum inhibitory concentration Psilocybe cubensis Psilocybin psilocybin +1

Psilocybin increases emotional empathy in patients with major depression.

Molecular Psychiatry June 1, 2025 Johannes Jungwirth, Robin von Rotz, Isabel Dziobek et al. 19 citations

Empathy plays a crucial role in interpersonal relationships and mental health. It is decreased in a variety of psychiatric disorders including major depression. Psilocybin, a promising candidate for treating depression, has been shown to acutely increase emotional empathy in healthy volunteers. However, no study has investigated this effect and its relevance for symptom improvement in a...

DOI: 10.1038/s41380-024-02875-0 (opens in new tab) Full text (opens in new tab) Mental health treatment Depression research Social connection Psilocybin therapy +1

Acute effects of psilocybin on attention and executive functioning in healthy volunteers: a systematic review and multilevel meta-analysis.

Psychopharmacology June 1, 2025 Parsa Yousefi, Morten P. Lietz, Fiachra O'Higgins et al. 7 citations

Psilocybin shows promise for treating neuropsychiatric disorders. However, insight into its acute effects on cognition is lacking. Given the significant role of executive functions in daily life and treatment efficacy, it is crucial to evaluate how psilocybin influences these cognitive domains. This meta-analysis aims to quantify the acute effects of psilocybin on executive functions and...

DOI: 10.1007/s00213-024-06742-2 (opens in new tab) Full text (opens in new tab) Psilocybin effects Psychedelic research Mental processing Accuracy +8

Psilocybin's lasting action requires pyramidal cell types and 5-HT2A receptors.

Nature June 1, 2025 Ling-Xiao Shao, Clara Liao, Pasha A. Davoudian et al. 75 citations

Psilocybin is a serotonergic psychedelic with therapeutic potential for treating mental illnesses1-4. At the cellular level, psychedelics induce structural neural plasticity5,6, exemplified by the drug-evoked growth and remodelling of dendritic spines in cortical pyramidal cells7-9. A key question is how these cellular modifications map onto cell-type-specific circuits to produce the...

DOI: 10.1038/s41586-025-08813-6 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Brain research Stress disorders

Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being.

Expert Opinion on Emerging Drugs June 1, 2025 Maria-Alejandra Umbacia, Marta Ximena Leon, Jose-Manuel Quintero et al.

Although long known for their psychoactive effects, psychedelic drugs have only recently been investigated for medicinal use. Psilocybin has attracted the greatest interest with studies suggesting that it may be a useful agent in psychiatry and in palliative care. Clinical trials that included psilocybin were searched in PubMed, Embase, and ClinicalTrials.gov, demonstrating that adult...

Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review.

Neuroscience & Biobehavioral Reviews June 1, 2025 Shakila Meshkat, Gunjan Malik, Richard J. Zeifman et al. 11 citations

Psilocybin, a serotonergic psychedelic, may have therapeutic benefits for Substance Use Disorders (SUDs), but its overall efficacy and safety remain uncertain. This systematic review assessed the safety and efficacy of psilocybin for SUDs through a systematic database search conducted via OVID on May 22, 2024, and summarized 26 ongoing clinical trials registered on clinicaltrials.gov. Among 16...